MX354473B - Formulación de aripiprazol liofilizado. - Google Patents
Formulación de aripiprazol liofilizado.Info
- Publication number
- MX354473B MX354473B MX2013014186A MX2013014186A MX354473B MX 354473 B MX354473 B MX 354473B MX 2013014186 A MX2013014186 A MX 2013014186A MX 2013014186 A MX2013014186 A MX 2013014186A MX 354473 B MX354473 B MX 354473B
- Authority
- MX
- Mexico
- Prior art keywords
- freeze
- aripiprazole
- dried
- dried aripiprazole
- aripiprazole formulation
- Prior art date
Links
- CEUORZQYGODEFX-UHFFFAOYSA-N Aripirazole Chemical compound ClC1=CC=CC(N2CCN(CCCCOC=3C=C4NC(=O)CCC4=CC=3)CC2)=C1Cl CEUORZQYGODEFX-UHFFFAOYSA-N 0.000 title abstract 6
- 229960004372 aripiprazole Drugs 0.000 title abstract 6
- 238000009472 formulation Methods 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title abstract 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 2
- 238000001035 drying Methods 0.000 abstract 1
- 230000008014 freezing Effects 0.000 abstract 1
- 238000007710 freezing Methods 0.000 abstract 1
- 239000013029 homogenous suspension Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000843 powder Substances 0.000 abstract 1
- 238000005507 spraying Methods 0.000 abstract 1
- 239000000725 suspension Substances 0.000 abstract 1
- 239000008215 water for injection Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Inorganic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Dermatology (AREA)
- Biochemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Psychiatry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Un objeto de la presente invención consiste en proveer una formulación de aripiprazol liofilizado en polvo, que denota buena dispersabilidad y que se dispersa fácilmente en una suspensión homogénea cuando se reconstituye con agua; la presente invención provee una formulación de aripiprazol liofilizado obtenida mediante un proceso que comprende los pasos de pulverización, con el fin de congelar una suspensión de aripiprazol que contiene (I) aripiprazol, (II) un vehículo para el aripiprazol y (III) agua para inyectables, y secado.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161494088P | 2011-06-07 | 2011-06-07 | |
PCT/JP2012/065180 WO2012169662A1 (en) | 2011-06-07 | 2012-06-07 | Freeze-dried aripiprazole formulation |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2013014186A MX2013014186A (es) | 2014-03-21 |
MX354473B true MX354473B (es) | 2018-03-07 |
Family
ID=46420491
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2013014186A MX354473B (es) | 2011-06-07 | 2012-06-07 | Formulación de aripiprazol liofilizado. |
Country Status (30)
Country | Link |
---|---|
US (3) | US11154507B2 (es) |
EP (1) | EP2717859B1 (es) |
JP (1) | JP6012637B2 (es) |
KR (1) | KR102014124B1 (es) |
CN (3) | CN103596557A (es) |
AR (2) | AR086682A1 (es) |
AU (1) | AU2012267810B2 (es) |
BR (1) | BR112013031459B1 (es) |
CA (1) | CA2837693C (es) |
CO (1) | CO6842019A2 (es) |
CY (1) | CY1118561T1 (es) |
DK (1) | DK2717859T3 (es) |
EA (1) | EA023951B1 (es) |
ES (1) | ES2599479T3 (es) |
HK (1) | HK1191245A1 (es) |
HR (1) | HRP20161357T1 (es) |
HU (1) | HUE031723T2 (es) |
IL (1) | IL229467A (es) |
JO (1) | JO3410B1 (es) |
LT (1) | LT2717859T (es) |
MX (1) | MX354473B (es) |
MY (1) | MY166052A (es) |
PL (1) | PL2717859T3 (es) |
PT (1) | PT2717859T (es) |
SG (1) | SG195046A1 (es) |
SI (1) | SI2717859T1 (es) |
TW (1) | TWI519320B (es) |
UA (1) | UA112186C2 (es) |
WO (1) | WO2012169662A1 (es) |
ZA (1) | ZA201308868B (es) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JOP20200109A1 (ar) | 2012-04-23 | 2017-06-16 | Otsuka Pharma Co Ltd | مستحضر قابل للحقن |
SI3362066T1 (sl) * | 2015-10-15 | 2022-04-29 | Les Laboratoires Servier | Kombinirana terapija za zdravljenje malignosti |
CN105663057A (zh) * | 2015-12-30 | 2016-06-15 | 中国药科大学 | 阿立哌唑长效混悬剂及其制备方法 |
AU2017303975A1 (en) | 2016-07-28 | 2019-03-21 | Mylan Laboratories Ltd, | Process for preparing sterile aripiprazole formulation |
WO2021233402A1 (zh) * | 2020-05-21 | 2021-11-25 | 江苏先声药业有限公司 | 一种含依匹哌唑药物组合物及其制备方法 |
CN112656767A (zh) * | 2021-01-22 | 2021-04-16 | 烟台东诚药业集团股份有限公司 | 一种依诺肝素钠注射制剂及其制备方法 |
EP4043008A1 (en) | 2021-02-15 | 2022-08-17 | Warszawskie Zaklady Farmaceutyczne Polfa S.A. | Method for the preparation of a pharmaceutical composition comprising aripiprazole |
WO2023083212A1 (zh) * | 2021-11-10 | 2023-05-19 | 广东东阳光药业有限公司 | 一种喹啉类药物的组合物 |
GR1010656B (el) * | 2023-03-23 | 2024-03-21 | Φαρματεν Α.Β.Ε.Ε., | Φαρμακευτικο σκευασμα που περιλαμβανει εναν ατυπο αντιψυχωσικο παραγοντα και μεθοδος για την παρασκευη αυτου |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5006528A (en) | 1988-10-31 | 1991-04-09 | Otsuka Pharmaceutical Co., Ltd. | Carbostyril derivatives |
GB9105705D0 (en) | 1991-03-18 | 1991-05-01 | Sandoz Ltd | Improvements in or relating to organic compounds |
ES2236700T3 (es) | 1993-11-19 | 2005-07-16 | Janssen Pharmaceutica N.V. | 1,2-benzazoles microencapsulados. |
GB9718986D0 (en) | 1997-09-09 | 1997-11-12 | Danbiosyst Uk | Controlled release microsphere delivery system |
US7521068B2 (en) * | 1998-11-12 | 2009-04-21 | Elan Pharma International Ltd. | Dry powder aerosols of nanoparticulate drugs |
MY129350A (en) | 2001-04-25 | 2007-03-30 | Bristol Myers Squibb Co | Aripiprazole oral solution |
AR033485A1 (es) | 2001-09-25 | 2003-12-26 | Otsuka Pharma Co Ltd | Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma |
US20050019607A1 (en) * | 2003-06-30 | 2005-01-27 | Franky So | OLED device with mixed emissive layer |
US20050032811A1 (en) * | 2003-08-06 | 2005-02-10 | Josiah Brown | Methods for administering aripiprazole |
PL1675573T4 (pl) * | 2003-10-23 | 2016-04-29 | Otsuka Pharma Co Ltd | Sterylny preparat do wstrzykiwań arypiprazolu o kontrolowanym uwalnianiu i sposób |
TWI371274B (en) * | 2003-10-23 | 2012-09-01 | Bristol Myers Squibb Co | Process for making sterile aripiprazole of desired mean particle size |
WO2005104193A1 (ja) | 2004-03-30 | 2005-11-03 | Fujitsu Limited | 電子ビーム露光データ補正方法 |
US7731873B2 (en) | 2005-08-09 | 2010-06-08 | Coopervision International Holding Company, Lp | Contact lens mold assemblies and systems and methods of producing same |
JP2009508859A (ja) * | 2005-09-15 | 2009-03-05 | エラン ファーマ インターナショナル リミテッド | ナノ粒子アリピプラゾール製剤 |
ES2661037T3 (es) * | 2007-07-31 | 2018-03-27 | Otsuka Pharmaceutical Co., Ltd. | Procedimientos para producir una suspensión de aripiprazol y una formulación liofilizada |
-
2012
- 2012-06-03 JO JOP/2012/0141A patent/JO3410B1/ar active
- 2012-06-06 TW TW101120275A patent/TWI519320B/zh active
- 2012-06-06 AR ARP120101990A patent/AR086682A1/es not_active Application Discontinuation
- 2012-06-07 EA EA201391818A patent/EA023951B1/ru not_active IP Right Cessation
- 2012-06-07 SI SI201230741A patent/SI2717859T1/sl unknown
- 2012-06-07 PT PT127311892T patent/PT2717859T/pt unknown
- 2012-06-07 CN CN201280027909.5A patent/CN103596557A/zh active Pending
- 2012-06-07 CA CA2837693A patent/CA2837693C/en active Active
- 2012-06-07 EP EP12731189.2A patent/EP2717859B1/en active Active
- 2012-06-07 CN CN201810450421.2A patent/CN108379231A/zh active Pending
- 2012-06-07 DK DK12731189.2T patent/DK2717859T3/en active
- 2012-06-07 PL PL12731189T patent/PL2717859T3/pl unknown
- 2012-06-07 BR BR112013031459-1A patent/BR112013031459B1/pt active IP Right Grant
- 2012-06-07 JP JP2013554727A patent/JP6012637B2/ja active Active
- 2012-06-07 CN CN201610937357.1A patent/CN106389357A/zh active Pending
- 2012-06-07 ES ES12731189.2T patent/ES2599479T3/es active Active
- 2012-06-07 HU HUE12731189A patent/HUE031723T2/hu unknown
- 2012-06-07 AU AU2012267810A patent/AU2012267810B2/en active Active
- 2012-06-07 US US14/124,459 patent/US11154507B2/en active Active
- 2012-06-07 WO PCT/JP2012/065180 patent/WO2012169662A1/en active Application Filing
- 2012-06-07 KR KR1020147000021A patent/KR102014124B1/ko active IP Right Grant
- 2012-06-07 MY MYPI2013702194A patent/MY166052A/en unknown
- 2012-06-07 LT LTEP12731189.2T patent/LT2717859T/lt unknown
- 2012-06-07 SG SG2013085568A patent/SG195046A1/en unknown
- 2012-06-07 MX MX2013014186A patent/MX354473B/es active IP Right Grant
- 2012-07-06 UA UAA201315553A patent/UA112186C2/uk unknown
-
2013
- 2013-11-17 IL IL229467A patent/IL229467A/en active IP Right Grant
- 2013-11-19 ZA ZA2013/08868A patent/ZA201308868B/en unknown
- 2013-12-30 CO CO13302836A patent/CO6842019A2/es unknown
-
2014
- 2014-05-14 HK HK14104543.8A patent/HK1191245A1/zh unknown
-
2016
- 2016-10-18 HR HRP20161357TT patent/HRP20161357T1/hr unknown
- 2016-11-03 CY CY20161101125T patent/CY1118561T1/el unknown
-
2021
- 2021-09-24 US US17/448,862 patent/US20220008341A1/en not_active Abandoned
- 2021-11-29 AR ARP210103281A patent/AR124163A2/es unknown
-
2023
- 2023-10-09 US US18/483,098 patent/US20240041774A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JO3410B1 (ar) | تركيبة أريبيبرازول مجفف بالتبريد | |
MX2021003256A (es) | Articulo abrasivo que incluye particulas abrasivas perfiladas. | |
WO2014047496A3 (en) | Spray drying microcapsules | |
MX2016003711A (es) | Particulas. | |
PH12015500900B1 (en) | A stabilized pemetrexed formulation | |
MX2015006324A (es) | Metodos para la fabricacion de polipeptidos proteoliticamente procesados. | |
CA2902795C (en) | Glycopyrrolate salts | |
WO2010079468A3 (en) | Delivery particle | |
WO2014086982A3 (en) | Stable metal compounds, their compositions and methods of their use | |
MX346373B (es) | Metodo para preparar harina de grano entero altamente dispersable con un contenido mejorado de avenantramida. | |
IL239894A0 (en) | Stable preparations containing hyaluronic acid and methods for their preparation | |
PH12017500370A1 (en) | Compound targeting il-23a and tnf-alpha and uses thereof | |
CA2905610C (en) | Hyaluronic acid derivatives | |
EP3043811A4 (en) | Compositions and methods for the delivery of molecules into live cells | |
WO2014199322A3 (en) | Wear resistant compositions with low particulate contamination and method of making those compositions | |
AU2018253594A1 (en) | Dihydroxyphenyl neurotransmitter compounds, compositions and methods | |
GB2514741A (en) | Composition for use as a paint binder | |
MX2014014868A (es) | Proceso para producir medios de cultivo celular. | |
MX2019002651A (es) | Metodos para preparar composiciones de revestimiento en polvo. | |
WO2015095240A3 (en) | Biosynthesis of 1-undecence and related terminal olefins | |
MX2012014304A (es) | Carboxamidas de pirazinilo como fungicidas. | |
WO2012125552A3 (en) | Methods of electric field induced delivery of compounds, compositions used in delivery, and system of delivery | |
WO2012157872A3 (ko) | 고화 방지 감미 소재 조성물 및 그의 제조 방법 | |
MX2016006790A (es) | Producto cosmetico con propiedades reparadoras del adn. | |
MX367773B (es) | Forma salina sólida de la alfa-6-mpeg6-o-hidroxicodona como agonistas opioides y sus usos. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |